Publications
Ralph A. Bradshaw: Scholar, leader, entrepreneur, Stahl, P.D. (2022), Ralph A. Bradshaw: Scholar, leader, entrepreneur. FASEB BioAdvances, 4: 691-693.
A Bell-Shaped Dose Response of Topical FGF-1 in Dermal Wound Healing of Aged Female BALB/cByJ Mice, Hagerott, B.N., Blumstein, A.J., McGarry, L.E., Cohen, H.M., Tenorio, C.A., Powell, B.D., Nagy, T. and Blaber, M. Journal of Proteins and Proteomics (2020)
Proliferation of Human Corneal Endothelia in Organ Culture Stimulated by Wounding and the Engineered Human Fibroblast Growth Factor 1 Derivative TTHX1114, David Eveleth, Sarah Pizzuto, Jessica Weant, Jennifer Jenkins-Eveleth, and Ralph A. Bradshaw Journal of Ocular Pharmacology and Therapeutics Ahead of Print (2020)
Cost Burden of Endothelial Keratoplasty in Fuchs Endothelial Dystrophy: Real-World Analysis of a Commercially Insured US Population (2014–2019), Deepinder K Dhaliwal, Viktor Chirikov, Jordana Schmier, Sanika Rege, Schalon Newton Dovepress (2022)
Fine-sampled Photographic Quantitation of Dermal Wound Healing Senescence in Aged BALB/cByJ Mice and Therapeutic Intervention with FGF-1, Mellers, A., Tenorio, C.A., Lacatusu, D., Powell, B., Patel, B., Harper, K.M. and Blaber, M. Advances in Wound Care 7, 409-418 (2018)
Engineering a Cysteine-Free Form of Human Fibroblast Growth Factor-1 for “2nd Generation” Therapeutic Application, Xia, X., Kumru, O.S., Blaber, S.I., Middaugh, C.R., Li, L., Ornitz, D.M., Sutherland, M.A., Tenorio, C. and Blaber, M., J. Pharm. Sci. 105, 1444-53 (2016)
Engineering a Cysteine-Free Form of Human Fibroblast Growth Factor-1 for “2nd Generation” Therapeutic Application, Xia, X., Kumru, O.S., Blaber, S.I., Middaugh, C.R., Li, L., Ornitz, D.M., Sutherland, M.A., Tenorio, C. and Blaber, M., J. Pharm. Sci. 105, 1444-53 (2016)
Mutation Choice to Eliminate Buried Free Cysteines in Protein Therapeutics, Xia, X., Longo, L.M. and Blaber, M. J. Pharm. Sci. 104, 566–576 (2015) PMID: 25312595
An empirical phase diagram approach to investigate conformational stability of “second-generation” functional mutants of acidic fibroblast growth factor (FGF-1), Alsenaidy, M.A., Wang, T., Kim, J.H., Joshi, S.B., Lee, J., Blaber, M., Volkin, D.B., and Middaugh, C.R., Prot. Sci. 21, 418-432 (2012) PMID: 221139
Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application, Xia, X., Babcock, J.P., Blaber, S.I., Harper, K.M. and Blaber, M., PLoS ONE 7(11): e48210 (2012) PMID: 23133616